Zusammenfassung
Neben ausgewählten Grundlagen über die Chemotherapie und Hormontherapie maligner Tumoren werden neue Therapiestrategien dargestellt. Darüber hinaus werden praxisorientierte Themen und aktuelle Therapieschemata behandelt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971–979
Chu E, DeVita VT Jr (2001) Principles of cancer management: Chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, Principles and practice of oncology. Lippincott, Philadelphia, pp 289–306
Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller WJ, Fruehauf S, Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller WJ, Fruehauf S (2009) Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma 50(10):1676–1686
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A (2007) Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 109: 1543–1549
Fruehauf S, Ehninger G, Hübel K, Topaly J, Goldschmidt H, Ho AD, Müller S, Moos M, Badel K, Calandra G (2010) Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin’s lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 45(2): 269–275
Fulda S, Debatin K-M (2005) Death receptor pathways as targets for anticancer therapy. In: Los M, Gibson SB (eds) Apoptotic pathways as targets for novel therapies in cancer and other diseases. Springer, Berlin Heidelberg New York, pp 57–78
Garg AK, Aggarwal BB (2005) Nuclear transcription factor-kB: a drug target for all seasons. In: Los M, Gibson SB (eds) Apoptotic pathways as targets for novel therapies in cancer and other diseases. Springer, Berlin Heidelberg New York, pp 297–322
Gilewski TA, Norton L (2001) Norton-Simon Hypothesis. In: Perry MC (ed) The Chemotherapy Source Book, Lippincott Williams & Wilkins, Philadelphia, pp 23–37
Hoffmann J, Sommer A, Schneider MR (2004) Hormonale Therapie maligner Tumoren. In: Zeller WJ, zur Hausen H (Hrsg) Onkologie IV. 5. ecomed, Landsberg, S1–S74
Ingold B, Schulz S, Budczies J, Neumann U, Ebert MP, Weichert W, Röcken C (2009) The role of vascular CXCR4 expression in colorectal carcinoma. Histopathology 55(5):576–586
Korsmeyer SJ, Zinkel SS (2001) Molecular biology of cancer: Apoptosis. iIn: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, Principles and practice of oncology. Lippincott, Philadelphia, pp 111–122
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16(2):214–218
Los M, Gibson SB (eds.) (2005) Apoptotic pathways as targets for novel therapies in cancer and other diseases. Springer, Berlin Heidelberg New York
Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Devière J, Salmon I, Van Laethem JL (2009) High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 100(9):1444–1451
Mizell J, Smith M, Li BD, Ampil F, Chu QD (2009) Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study. Ann Surg Oncol 16(10):2711–2716
Norton L (1987) Synopsis of cancer growth kinetics and chemotherapy. In Silver RT, Lauper RD, Jarowski C (eds) A synopsis of cancer chemotherapy Yorke Medical Books, New York, pp XI–XXV
Quiles-Perez R, Muño z-Gámez JA, Ruiz-Extremera A, O’Valle F, Sanjuán-Nuñez L, Martín-Alvarez AB, Martín-Oliva D, Caballero T, Muñoz de Rueda P, León J, Gonzalez R, Muntané J, Oliver FJ, Salmerón J (2010) Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 51(1):255–266
Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG. Leukemia 19:1198–1206
Radujkovic A, Topaly J, Fruehauf S, Zeller WJ (2006) Combination treatment of imatinib-sensitive and-resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. Anticancer Res 26:2169–2177
Radujkovic A, Topaly J (2008) Tyrokinase-gerichtete Therapien in der Onkologie. In: Onkologie (Zeller, WJ, zur Hausen H, Hrsg) ecomed, Landsberg, 1–15
Sluyser M.(ed.): Application of Apoptosis to Cancer Treatment. Springer, Dordrecht 2005
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
Topaly J, Fruehauf S, Ho AD, Zeller WJ (2002a) Rationale for combination therapy of chronic myelogeneous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 86:1487–1493
Topaly J, Zeller WJ, Fruehauf S (2002b) Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 119:3–14
Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogeneous leukemia cells. Leukemia 15:342–347
Wang DF, Lou N, Zeng CG, Zhang X, Chen FJ (2009) Expression of CXCL12/CXCR4 and its correlation to prognosis in esophageal squamous cell carcinoma. Ai Zheng 28(2):154
Wesselborg S, Lauber K (2005) Mechanisms of anticancer drug action. In: Los M, Gibson SB (eds) Apoptotic pathways as targets for novel therapies in cancer and other diseases. Springer, Berlin Heidelberg New York, pp 31–55
Zeller WJ (2005) Grundlagen der Chemotherapie und der Hormontherapie maligner Tumoren. In: Zeller WJ, zur Hausen H (Hrsg.) Onkologie, IV-1. ecomed, Landsberg, S1–S20
Zeller WJ (1995) Zytostatika (klinisch etablierte Verbindungen). In: Zeller WJ, zur Hausen H (Hrsg.) Onkologie, IV-3, ecomed, Landsberg
Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Egrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113(24):6215–6224
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fruehauf, S., Radujkovic, A., Topaly, J., Zeller, W.J. (2010). Chemotherapie. In: Siewert, J.R., Rothmund, M., Schumpelick, V. (eds) Praxis der Viszeralchirurgie Onkologische Chirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-03808-2_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-03808-2_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-03807-5
Online ISBN: 978-3-642-03808-2
eBook Packages: Medicine (German Language)